PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.19%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 2.48%. Joel Greenblatt would verify if operating margins keep pace with this top-line surge.
1.77%
Gross profit growth 50-75% of Medical - Pharmaceuticals median of 3.11%. Guy Spier might worry about insufficient cost control or weaker pricing.
-21.19%
Negative EBIT growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-22.23%
Negative operating income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
9.10%
Positive net income growth while Medical - Pharmaceuticals median is negative. Peter Lynch would view this as a notable competitive advantage.
9.10%
EPS growth of 9.10% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could compound over time.
9.10%
Diluted EPS growth of 9.10% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight edge that could improve over time.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.07%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see an advantage if others are still diluting.
15.38%
Dividend growth of 15.38% while Medical - Pharmaceuticals median is flat. Walter Schloss might appreciate at least a modest improvement.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
145.37%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 50.24%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
35.19%
5Y revenue/share growth 1.25-1.5x Medical - Pharmaceuticals median of 24.30%. Mohnish Pabrai might attribute the outperformance to scale or brand strength.
31.75%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 9.77%. Joel Greenblatt might see a short-term competitive advantage at play.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
144.02%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 75.94% over a decade. Joel Greenblatt might see a standout compounder of earnings.
19.91%
Below 50% of Medical - Pharmaceuticals median. Jim Chanos would suspect deeper problems limiting mid-term profit potential.
28.78%
3Y net income/share CAGR near Medical - Pharmaceuticals median. Charlie Munger sees standard sector-level performance in the last few years.
295.46%
Equity/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 21.46% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
76.61%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 0.12%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
35.05%
Positive short-term equity/share CAGR while Medical - Pharmaceuticals is negative. Peter Lynch finds a relative advantage vs. sector-level slowdown.
361.54%
Dividend/share CAGR of 361.54% while Medical - Pharmaceuticals is zero. Walter Schloss sees a minor improvement that could compound if the firm maintains consistent raises.
150.00%
5Y dividend/share CAGR of 150.00% while Medical - Pharmaceuticals is zero. Walter Schloss sees at least some improvement that could compound over time.
87.50%
3Y dividend/share CAGR of 87.50% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight advantage if the firm is at least inching up payouts.
1721.43%
Receivables growth far exceeding Medical - Pharmaceuticals median. Jim Chanos suspects potential red flags in revenue quality.
4.84%
Inventory growth of 4.84% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
10.68%
We expand assets while Medical - Pharmaceuticals is negative. Peter Lynch sees a possible advantage if expansions align with profitable markets or a recovering cycle.
3.47%
Positive BV/share change while Medical - Pharmaceuticals median is negative. Peter Lynch finds a strong advantage vs. peers failing to expand equity.
75.11%
Slightly rising debt while Medical - Pharmaceuticals median is deleveraging. Peter Lynch wonders if the firm lags behind peers in risk control or invests in more expansions.
No Data
No Data available this quarter, please select a different quarter.
8.24%
SG&A growth far above Medical - Pharmaceuticals median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.